Login / Signup

Pilot study in pharmacogenomic management of empagliflozin in type 2 diabetes mellitus patients.

Mahdieh JamalizadehMandana HasanzadNegar SarhangiFarshad SharifiFarshad SharifiBagher Larijani
Published in: Journal of diabetes and metabolic disorders (2021)
(rs11646054) on the clinical efficacy of empagliflozin were negligible.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • chronic kidney disease
  • peritoneal dialysis
  • patient reported outcomes
  • clinical decision support